Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02497235 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02497235 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 11 participants.
The verdict
NCT02497235, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the brain cholesterol 24S-hydroxylase (CH24H) enzyme occupancy of TAK-935 after single oral dose in healthy participants using the positron emission tomography (PET) ligand \[18F\]MNI-792 and PET imaging and to determine the relationship of occupancy to TAK-935 exposure.
Interventions
- DRUG TAK-935
- DRUG [18F]MNI-792 (tracer)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02497235
The ClinicalTrials.gov registry entry for NCT02497235 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-935 is the first listed.
NCT02497235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02497235 about?
NCT02497235 is a clinical study titled "A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935". The purpose of this study is to determine the brain cholesterol 24S-hydroxylase (CH24H) enzyme occupancy of TAK-935 after single oral dose in healthy participants using the positron emission tomography (PET) ligand \[18F\]MNI-792 and PET imaging and to determine the relationship of occupancy to TAK-...
What is the current status of trial NCT02497235?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2015-07. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02497235?
The interventions under investigation include: TAK-935 (DRUG), [18F]MNI-792 (tracer) (DRUG).
Who is sponsoring clinical trial NCT02497235?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.